First-Line Crizotinib versus Chemotherapy in <i>ALK</i>-Positive Lung CancerBenjamin Solomon, Fiona Blackhall, Jolanda Paolini et al.|New England Journal of Medicine|2014Cited by 3.2k
Crizotinib in ROS1-rearranged advanced non-small-cell lung cancer (NSCLC): updated results, including overall survival, from PROFILE 1001A. Shaw, S.‐H.I. Ou, G.J. Riely et al.|Annals of Oncology|2019Cited by 587
Antitumor activity of crizotinib in lung cancers harboring a MET exon 14 alterationAlexander Drilon, Paul K. Paik, Jeffrey W. Clark et al.|Nature Medicine|2020Cited by 399
OA12.02 Updated Antitumor Activity of Crizotinib in Patients with MET Exon 14-Altered Advanced Non-Small Cell Lung CancerAlexander Drilon, Paul K. Paik, Jeffrey W. Clark et al.|Journal of Thoracic Oncology|2018Cited by 35